Better Buy: Editas Medicine or Sangamo Therapeutics?
Gene editing holds tremendous promise to help patients and potentially cure a multitude of inherited diseases. Editas Medicine (NASDAQ: EDIT) and Sangamo Therapeutics (NASDAQ: SGMO) employ technologies aimed at removing, replacing, or editing sections of the human genome.
Editas focuses on a relatively recent technology called CRISPR while Sangamo uses several technologies including what is called zinc finger technology. Both approaches allow for precise gene editing by breaking the DNA strand and either inserting new DNA sequences or deleting sections of damaged or mutated DNA.
Image source: Getty Images.
Source Fool.com
